Dr. Lal PathLabs Limited

NSEI:LALPATHLAB Stok Raporu

Piyasa değeri: ₹261.4b

Dr. Lal PathLabs Yönetim

Yönetim kriter kontrolleri 2/4

Dr. Lal PathLabs' CEO'su Shankha Banerjee, May2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.027% doğrudan sahiptir ve bu hisselerin değeri ₹ 76.03M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 5.5 yıldır.

Anahtar bilgiler

Shankha Banerjee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliği0.03%
Yönetim ortalama görev süresi4.5yrs
Yönetim Kurulu ortalama görev süresi5.5yrs

Son yönetim güncellemeleri

Recent updates

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

CEO

Shankha Banerjee

less than a year

Görev süresi

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Arvind Lal
Executive Chairman29.7yrs₹30.14m32.93%
₹ 86.1b
Om Manchanda
MD & Director4.5yrs₹46.45m1.04%
₹ 2.7b
Vandana Lal
Executive Directorno data₹24.18m19.3%
₹ 50.5b
Shankha Banerjee
Chief Executive Officerless than a yearVeri yok0.027%
₹ 69.8m
Ved Goel
Group CFO & CEO of International Business6.2yrs₹7.30m0.014%
₹ 37.8m
Jai Meena
Chief Operating Officer2.5yrsVeri yokVeri yok
Munender Soperna
Chief Information & Digital Officer10.3yrsVeri yok0.025%
₹ 65.6m
Vinay Gujral
Company Secretary & Compliance Officer1.5yrsVeri yok0.00066%
₹ 1.7m
Manoj Garg
Group Chief Human Resources Officer10yrsVeri yok0.033%
₹ 85.3m

4.5yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim: LALPATHLAB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Arvind Lal
Executive Chairman29.7yrs₹30.14m32.93%
₹ 86.1b
Om Manchanda
MD & Director13.7yrs₹46.45m1.04%
₹ 2.7b
Vandana Lal
Executive Director29.7yrs₹24.18m19.3%
₹ 50.5b
Arun Duggal
Lead Independent Director1.7yrs₹3.85mVeri yok
Rajit Mehta
Independent Director1.3yrs₹1.56mVeri yok
Rahul Sharma
Non Executive Director19.3yrs₹2.65m0.024%
₹ 62.8m
Rohit Bhasin
Independent Non-Executive Director1.9yrs₹2.60mVeri yok
Somya Satsangi
Independent Director5.7yrs₹2.70mVeri yok
Archana Erdmann
Non-Executive Director5.4yrs₹2.25m1.85%
₹ 4.8b
Gurinder Singh Kalra
Independent Director1.3yrs₹1.56mVeri yok

5.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LALPATHLAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).